Update on donor-derived infections in liver transplantation

Authors

  • Ignacio A. Echenique,

    1. Division of Infectious Diseases
    2. Northwestern University Transplant Outcomes Research Collaboration, Northwestern University Feinberg School of Medicine, Chicago, IL
    Search for more papers by this author
  • Michael G. Ison

    Corresponding author
    1. Division of Infectious Diseases
    2. Division of Organ Transplantation
    • Northwestern University Transplant Outcomes Research Collaboration, Northwestern University Feinberg School of Medicine, Chicago, IL
    Search for more papers by this author

Address reprint requests to Michael G. Ison, M.D., M.S., F.I.D.S.A., Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Suite 900, Chicago, IL 60611. Telephone: 312-695-4186; FAX: 312-695-5088; E-mail: mgison@northwestern.edu

Abstract

Advances in surgical techniques, immunosuppressive medications, and robust infectious disease prophylaxis have resulted in liver transplantation becoming the treatment of choice for patients with end-stage liver disease and unresectable hepatocellular carcinoma. Nonetheless, organ transplantation is not without risk. Unexpected donor-derived disease transmission is a newly recognized risk that complicates approximately 0.2% of all organ transplants. We review the epidemiology of donor-derived infectious diseases and methods of risk mitigation with a focus on liver transplantation. Liver Transpl 19:575–585, 2013. © 2013 AASLD.

Ancillary